BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Covalent fragment technologies for therapeutic target discovery an
 d validation
DTSTART:20240423T161500
DTEND:20240423T171500
DTSTAMP:20261002T015024Z
UID:ed0cfe4425c80ef591feabb8a85b0841a9c51b5ff02c69f196d76886
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Dr. Jakob Bush\, GSK\nAdvances in genomic analyses enabl
 e the identification of proteins that are associated with disease. In orde
 r to validate these targets for prioritisation in drug discovery programme
 s\, tool molecules are required to demonstrate that a ligand can have a di
 sease-modifying effect. Currently\, as tools are reported for only a fract
 ion of the proteome\, platforms for expedient ligand discovery are essenti
 al to leverage insights from genomic analyses. The use of electrophilic fr
 agment libraries has emerged within chemical biology as a powerful approac
 h for the identification of fragment–protein interactions\, particularly
  in a cellular context.
LOCATION:BCH 2218 https://plan.epfl.ch/?room==BCH%202218
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR